Key facts
- Savanna Biotherapeutics’s last known valuation is $49.0M (Jun 2025).
- It has raised $37.3M across 1 recorded rounds; the latest was Early Stage VC ($13.0M) in Jun 2025.
- Notable investors include Medical Excellence Capital, National Institutes of Neurological Disorders and Stroke.
- Savanna Biotherapeutics has filed 1 Form D with the SEC, most recently Jun 2025 ($13.0M sold to 30 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Savanna Biotherapeutics
Create free account
No card required
Funding rounds
1 roundsAbout Savanna Biotherapeutics
The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- Aliso Viejo, CA, United States
- Founded
- 2020
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Savanna Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Savanna Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Savanna Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.